Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CANbridge Says C5 mAb Effective in Early Trial for Complement Diseases

publication date: Feb 7, 2022

CANbridge Pharma of Beijing reported positive data from a Singapore Phase I trial of its long-acting anti-C5 complement recombinant human mAb. CAN106 is a novel, long-acting mAb designed to neutralize C5, a key component of the complement system. In patients with paroxysmal nocturnal hemoglobinuria (PNH), division of C5 can cause cell lysis of red blood cells. The Phase I trial showed CAN106 to be well-tolerated while lowering levels of free C5 by 99%. CANbridge, a rare disease and oncology company, has also been approved to start CAN106 trials in China for PNH. More details....

Stock Symbol: (HK: 1228)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.